Novel signatures of prostate cancer progression and therapeutic resistance

Jason Wang, Reuben Ben-David, Reza Mehrazin, Wei Yang, Ashutosh K. Tewari, Natasha Kyprianou

Research output: Contribution to journalReview articlepeer-review


Introduction: The extensive heterogeneity of prostate cancer (PCa) and multilayered complexity of progression to castration-resistant prostate cancer (CRPC) have contributed to the challenges of accurately monitoring advanced disease. Profiling of the tumor microenvironment with large-scale transcriptomic studies have identified gene signatures that predict biochemical recurrence, lymph node invasion, metastases, and development of therapeutic resistance through critical determinants driving CRPC. Areas Covered: This review encompasses understanding of the role of different molecular determinants of PCa progression to lethal disease including the phenotypic dynamic of cell plasticity, EMT-MET interconversion, and signaling-pathways driving PCa cells to advance and metastasize. The value of liquid biopsies encompassing circulating tumor cells and extracellular vesicles to detect disease progression and emergence of therapeutic resistance in patients progressing to lethal disease is discussed. Relevant literature was added from PubMed portal. Expert Opinion: Despite progress in the tumor-targeted therapeutics and biomarker discovery, distant metastasis and therapeutic resistance remain the major cause of mortality in patients with advanced CRPC. No single signature can encompass the tremendous phenotypic and genomic heterogeneity of PCa, but rather multi-threaded omics-derived and phenotypic markers tailored and validated into a multimodal signature.

Original languageEnglish
Pages (from-to)1195-1206
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Issue number12
StatePublished - 2023


  • Cell plasticity
  • extracellular vesicles
  • lethal disease
  • metastasis
  • recurrent tumors
  • treatment failure


Dive into the research topics of 'Novel signatures of prostate cancer progression and therapeutic resistance'. Together they form a unique fingerprint.

Cite this